Updates are available Correction dated 2022-06-16
Click to view Correction: https://doi.org/10.1038/s41467-022-30987-0
-
Authors
Braun, Theodore P. https://orcid.org/0000-0002-6248-2143
Okhovat, Mariam
Coblentz, Cody
Carratt, Sarah A. https://orcid.org/0000-0003-2493-6789
Foley, Amy
Schonrock, Zachary
Curtiss, Brittany M.
Nevonen, Kimberly https://orcid.org/0000-0003-0198-1624
Davis, Brett https://orcid.org/0000-0001-7985-1921
Garcia, Brianna
LaTocha, Dorian
Weeder, Benjamin R. https://orcid.org/0000-0002-4128-5861
Grzadkowski, Michal R.
Estabrook, Joey C.
Manning, Hannah G.
Watanabe-Smith, Kevin
Jeng, Sophia
Smith, Jenny L.
Leonti, Amanda R.
Ries, Rhonda E.
McWeeney, Shannon https://orcid.org/0000-0001-8333-6607
Di Genua, Cristina
Drissen, Roy https://orcid.org/0000-0002-8574-5014
Nerlov, Claus https://orcid.org/0000-0002-0544-735X
Meshinchi, Soheil
Carbone, Lucia
Druker, Brian J. https://orcid.org/0000-0001-8331-8206
Maxson, Julia E.
- License Information
-
More Information
Article History
Received: 14 May 2019
Accepted: 4 November 2019
First Online: 29 November 2019
Competing interests
: B.J.D. potential competing interests—Consultant: Monojul, Patient True Talk; SAB: Aileron Therapeutics, ALLCRON, Cepheid, Gilead Sciences, Vivid Biosciences, Celgene & Baxalta (inactive); SAB & Stock: Aptose Biosciences, Blueprint Medicines, Beta Cat, GRAIL, Third Coast Therapeutics, CTI BioPharma (inactive); Scientific Founder & Stock: MolecularMD; Board of Directors & Stock: Amgen; Board of Directors: Burroughs Wellcome Fund, CureOne; Joint Steering Committee: Beat AML LLS; Clinical Trial Funding: Novartis, Bristol-Myers Squibb, Pfizer; Royalties: OHSU #606-Novartis exclusive license, OHSU #2573; Dana-Farber Cancer Institute #2063-Merck exclusive license. The remaining authors declare no competing interests.
